



## Altimune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

May 5, 2022

GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.

Altimune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update.

### Conference Call Information:

Date: Thursday, May 12  
Time: 8:30 am Eastern Time  
Domestic Dial-in: (800) 225-9448  
International Dial-in: (203) 518-9708  
Conference ID: ALTQ122  
Webcast: <https://edge.media-server.com/mmc/p/j5i9f735>

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Investor and Media Contact:

Richard Eisenstadt  
Chief Financial Officer  
Phone: 240-654-1450  
[reisenstadt@altimmune.com](mailto:reisenstadt@altimmune.com)



Source: Altimune, Inc